| 5.37 0.15 (2.87%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.64 | 1-year : | 7.22 |
| Resists | First : | 5.69 | Second : | 6.19 |
| Pivot price | 5.41 |
|||
| Supports | First : | 4.88 | Second : | 4.06 |
| MAs | MA(5) : | 5.25 |
MA(20) : | 5.38 |
| MA(100) : | 5.21 |
MA(250) : | 5.67 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 26.4 | D(3) : | 26 |
| RSI | RSI(14): 51.4 |
|||
| 52-week | High : | 9.11 | Low : | 3.85 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EXAI ] has closed above bottom band by 45.0%. Bollinger Bands are 36.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.43 - 5.45 | 5.45 - 5.46 |
| Low: | 5.19 - 5.21 | 5.21 - 5.23 |
| Close: | 5.33 - 5.37 | 5.37 - 5.4 |
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Fri, 26 Jul 2024
Mitsubishi UFJ Trust & Banking Corp Sells 25,530 Shares of Exscientia plc (NASDAQ:EXAI) - Defense World
Thu, 18 Jul 2024
Exscientia to buy full rights to lead asset (NASDAQ:EXAI) - Seeking Alpha
Wed, 10 Jul 2024
Exscientia Extends Collaboration With AWS To Use AI And Machine Learning Services - Nasdaq
Wed, 10 Jul 2024
Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery - Business Wire
Mon, 17 Jun 2024
Shareholders that lost money on Exscientia plc(EXAI) Urged to Join Class Action - Contact The Gross Law Firm to Learn More - PR Newswire
Sat, 25 May 2024
Analysts Are Upgrading Exscientia plc (NASDAQ:EXAI) After Its Latest Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 126 (M) |
| Shares Float | 93 (M) |
| Held by Insiders | 38.5 (%) |
| Held by Institutions | 38.6 (%) |
| Shares Short | 3,750 (K) |
| Shares Short P.Month | 4,480 (K) |
| EPS | -1.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.61 |
| Profit Margin | 0 % |
| Operating Margin | -526.8 % |
| Return on Assets (ttm) | -18.4 % |
| Return on Equity (ttm) | -33.3 % |
| Qtrly Rev. Growth | -8.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.15 |
| EBITDA (p.s.) | -1.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -105 (M) |
| Levered Free Cash Flow | -89 (M) |
| PE Ratio | -3.98 |
| PEG Ratio | -0.5 |
| Price to Book value | 2.04 |
| Price to Sales | 34.6 |
| Price to Cash Flow | -6.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|